Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
36.34
-0.26 (-0.72%)
At close: Apr 28, 2026, 4:00 PM EDT
36.34
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Cogent Biosciences Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Cogent Biosciences stock have an average target of 36.21, with a low estimate of 9.00 and a high estimate of 67. The average target predicts a decrease of -0.36% from the current stock price of 36.34.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 17, 2026.
Analyst Ratings
The average analyst rating for Cogent Biosciences stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 7 | 7 |
| Buy | 3 | 3 | 4 | 5 | 4 | 4 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 14 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $55 | Buy | Reiterates | $55 | +51.35% | Mar 17, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $55 | Strong Buy | Initiates | $55 | +51.35% | Mar 16, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $39 → $52 | Buy | Maintains | $39 → $52 | +43.09% | Feb 18, 2026 |
| Wedbush | Wedbush | Buy Reiterates $55 | Buy | Reiterates | $55 | +51.35% | Jan 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $52 | Strong Buy | Maintains | $50 → $52 | +43.09% | Jan 6, 2026 |
Financial Forecast
Revenue This Year
19.99M
Revenue Next Year
366.46M
from 19.99M
Increased by 1,733.58%
EPS This Year
-2.23
from -2.55
EPS Next Year
-0.64
from -2.23
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 44.0M | 830.2M | ||||||
| Avg | 20.0M | 366.5M | ||||||
| Low | n/a | 114.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 4,054.1% | ||||||
| Avg | - | 1,733.6% | ||||||
| Low | - | 473.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.73 | 1.64 | ||||||
| Avg | -2.23 | -0.64 | ||||||
| Low | -2.78 | -2.27 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.